Tags

Type your tag names separated by a space and hit enter

Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications.
J Drugs Dermatol. 2016 Mar; 15(3):325-32.JD

Abstract

Although the broad-spectrum anti-parasitic effects of the avermectin derivative ivermectin are well documented, its anti-inflammatory activity has only recently been demonstrated. For over 25 years, ivermectin has been used to treat parasitic infections in mammals, with a good safety profile that may be attributed to its high affinity to invertebrate neuronal ion channels and its inability to cross the blood-brain barrier in humans and other mammals. Numerous studies report low rates of adverse events, as an oral treatment for parasitic infections, scabies and head lice. Ivermectin has been used off-label to treat diseases associated with Demodex mites, such as blepharitis and demodicidosis. New evidence has linked Demodex mites to rosacea, a chronic inflammatory disease. Ivermectin has recently received FDA and EU approval for the treatment of adult patients with inflammatory lesions of rosacea, a disease in which this agent has been shown to be well tolerated. After more than 25 years of use, ivermectin continues to provide a high margin of safety for a growing number of indications based on its anti-parasitic and anti-inflammatory activities.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26954318

Citation

Kircik, Leon H., et al. "Over 25 Years of Clinical Experience With Ivermectin: an Overview of Safety for an Increasing Number of Indications." Journal of Drugs in Dermatology : JDD, vol. 15, no. 3, 2016, pp. 325-32.
Kircik LH, Del Rosso JQ, Layton AM, et al. Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol. 2016;15(3):325-32.
Kircik, L. H., Del Rosso, J. Q., Layton, A. M., & Schauber, J. (2016). Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. Journal of Drugs in Dermatology : JDD, 15(3), 325-32.
Kircik LH, et al. Over 25 Years of Clinical Experience With Ivermectin: an Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol. 2016;15(3):325-32. PubMed PMID: 26954318.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. AU - Kircik,Leon H, AU - Del Rosso,James Q, AU - Layton,Alison M, AU - Schauber,Jürgen, PY - 2016/3/9/entrez PY - 2016/3/10/pubmed PY - 2016/12/15/medline SP - 325 EP - 32 JF - Journal of drugs in dermatology : JDD JO - J Drugs Dermatol VL - 15 IS - 3 N2 - Although the broad-spectrum anti-parasitic effects of the avermectin derivative ivermectin are well documented, its anti-inflammatory activity has only recently been demonstrated. For over 25 years, ivermectin has been used to treat parasitic infections in mammals, with a good safety profile that may be attributed to its high affinity to invertebrate neuronal ion channels and its inability to cross the blood-brain barrier in humans and other mammals. Numerous studies report low rates of adverse events, as an oral treatment for parasitic infections, scabies and head lice. Ivermectin has been used off-label to treat diseases associated with Demodex mites, such as blepharitis and demodicidosis. New evidence has linked Demodex mites to rosacea, a chronic inflammatory disease. Ivermectin has recently received FDA and EU approval for the treatment of adult patients with inflammatory lesions of rosacea, a disease in which this agent has been shown to be well tolerated. After more than 25 years of use, ivermectin continues to provide a high margin of safety for a growing number of indications based on its anti-parasitic and anti-inflammatory activities. SN - 1545-9616 UR - https://brain.unboundmedicine.com/medline/citation/26954318/Over_25_Years_of_Clinical_Experience_With_Ivermectin:_An_Overview_of_Safety_for_an_Increasing_Number_of_Indications_ L2 - http://jddonline.com/articles/dermatology/S1545961616P0325X DB - PRIME DP - Unbound Medicine ER -